Table 6. [Targeted Treatment of PIK3CA-Related Overgrowth Spectrum]. - GeneReviews® - NCBI Bookshelf

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024.

Cover of GeneReviews®

GeneReviews^® [Internet].

GeneReviews by Title

Table 6.

Targeted Treatment of PIK3CA-Related Overgrowth Spectrum

Treatment	Dosage	Indication	Mechanism
Alpelisib (VIJOICE^®) ¹	Treatment regimen in persons age 2 to <18 yrs: Initial dose 50 mg taken orally 1x/day ² w/food In those age ≥6 yrs, dose may be ↑ to 125 mg 1x/day after 24 wks of treatment. ³ Treatment regimen in persons ≥18 yrs: 250 mg taken orally 1x/day ¹ w/food	The treatment of adult & pediatric patients age ≥2 yrs w/severe manifestations of PROS who require systemic therapy	PI3K inhibitor

: PROS = PIK3CA-related overgrowth spectrum
1.: This medication has been approved specifically for the reduction of overgrowth, vascular lesions, and other functional complications. To date, it is unknown whether this drug has any efficacy in treating the neurologic manifestations of PROS (as, e.g., in MCAP syndrome).
2.: The tablet should be taken at approximately the same time every day
3.: A dose reduction back to 50 gm/day may be considered in those with an adverse reaction on the higher dose.

From: PIK3CA-Related Overgrowth Spectrum

Copyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.

GeneReviews by Title

Views

Cite this Page
Mirzaa G, Graham JM Jr, Keppler-Noreuil K. PIK3CA-Related Overgrowth Spectrum. 2013 Aug 15 [Updated 2023 Apr 6]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Table 6. [Targeted Treatment of PIK3CA-Related Overgrowth Spectrum].
PDF version of this page (2.4M)

Bulk Download

Bulk download GeneReviews data from FTP

GeneReviews Links

Similar articles in PubMed

Review Beckwith-Wiedemann Syndrome.[GeneReviews(®). 1993]
Review Beckwith-Wiedemann Syndrome.
Shuman C, Kalish JM, Weksberg R. GeneReviews(®). 1993
PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.[Am J Med Genet A. 2015]
PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Keppler-Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC, Alomari A, Ezaki M, Dobyns W, Biesecker LG. Am J Med Genet A. 2015 Feb; 167A(2):287-95. Epub 2014 Dec 31.
Molecular characterization of 13 patients with PIK3CA-related overgrowth spectrum using a targeted deep sequencing approach.[Am J Med Genet A. 2024]
Molecular characterization of 13 patients with PIK3CA-related overgrowth spectrum using a targeted deep sequencing approach.
de Kock L, Cuillerier A, Gillespie M, Couse M, Hartley T, Mears W, Bernier FP, Chudley AE, Frosk P, Nikkel SM, et al. Am J Med Genet A. 2024 Mar; 194(3):e63466. Epub 2023 Nov 10.
PIK3CA-Related Overgrowth Spectrum From Diagnosis to Targeted Therapy: A Case of CLOVES Syndrome Treated With Alpelisib.[Front Pediatr. 2021]
PIK3CA-Related Overgrowth Spectrum From Diagnosis to Targeted Therapy: A Case of CLOVES Syndrome Treated With Alpelisib.
Pagliazzi A, Oranges T, Traficante G, Trapani C, Facchini F, Martin A, Semeraro A, Perrone A, Filippeschi C, Giglio S. Front Pediatr. 2021; 9:732836. Epub 2021 Sep 9.
Review [PIK3CA-related overgrowth syndrome (PROS)].[Nephrol Ther. 2017]
Review [PIK3CA-related overgrowth syndrome (PROS)].
Venot Q, Canaud G. Nephrol Ther. 2017 Apr; 13 Suppl 1:S155-S156.

See reviews...See all...

Recent Activity

Clear Turn Off Turn On

Table 6. [Targeted Treatment of PIK3CA-Related Overgrowth Spectrum]. - GeneRevie...
Table 6. [Targeted Treatment of PIK3CA-Related Overgrowth Spectrum]. - GeneReviews®

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on